PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...

"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...

First-ever FDA approval for gene therapy directly administered to the brain - - Priority review voucher granted - - Broad label including children and ... that results in the inability to synthesize ...

AbbVie today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an acute ...

Their products are most likely fakes and have subtle differences on the label. Mind Lab Pro is unlikely to cause side effects. However, it may cause an excessive increase in dopamine if you already ...

The FDA has followed in the footsteps of its European counterparts and granted accelerated approval to PTC Therapeutics’ gene ...

With young people in the grip of a cost-of-living crisis, TikTok creators are turning grocery runs into rich-girl-coded ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

AADC deficiency results in the inability to synthesize dopamine, a neurotransmitter essential for motor ... The approval is ...

College students have opportunities to bend or break the rules after leaving home. It can be dangerous for those who take ...

The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients ...

The emraclidine trial program is also supposed to include a 52-week open label extension trial EMPOWER-3 to assess ...